Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS)-Reference-Cited by-同舟云学术

Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS)

Published:1994-07 Issue:4 Volume:2 Page:213-222
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Hollen Patricia J.,Gralla Richard J.,Kris Mark G.,Cox Christopher

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/BF00365725.pdf

Reference43 articles.

1. Aaronson NK (1991) Methodological issues in assessing the quality of life of cancer patients. Cancer 67:844?850

2. Aaronson NK, Meyerowitz BE, Bard M, et al (1991) Quality of life research in oncology: past achievements and future priorities. Cancer 67:839?843

3. Bakker W, Van Oosterom AT, Aaronson NK, et al (1986) Vindesine, cisplatin, and bleomycin combination chemotherapy in non-small cell lung cancer: survival and quality of life. Eur J Cancer Clin Oncol 22:963?970

4. Burke MT, Gralla R, Kris M, et al (1985) Subjective evaluation in non-small cell lung cancer: comparison of Karnofsky performance status with a patient generated visual analogue scale measuring activity. In: Proceedings of the IVth World Conference on Lung Cancer, vol 4, p 42

5. Carmines EG, Zeller RA (1979) Reliability and validity assessment. Sage, Beverly Hills, Calif

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON);Lung Cancer;2023-12

2. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes;European Journal of Cancer;2023-04

3. Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials;JNCI Cancer Spectrum;2023-01-20

4. Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer;Lung Cancer;2022-03

5. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1;Journal of Thoracic Oncology;2021-04